Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$32.39

-0.53 (-1.61%)

, PFE

Pfizer

$33.28

0.06 (0.18%)

07:41
07/14/17
07/14
07:41
07/14/17
07:41

Leerink sees significant optionality for AstraZeneca beyond MYSTIC trial

Leerink analyst Seamus Fernandez said he sees significant optionality for AstraZeneca (AZN) beyond the "mega-catalyst" of the MYSTIC trial in non-small cell lung cancer, as he believes several 2017 and 2018 readouts from underappreciated pipeline assets could lead to upside for the shares. If MYSTIC fails, Astra's "massive" SG&A spend gives it flexibility to mute the bottom-line impact. If it is successful, he believes potential acquirers such as Pfizer (PFE) or Novartis (NVS) could see "an attractive target to plunder," Fernandez tells investors. He keeps an Outperform rating and $36 price target on AstraZeneca ADRs.

AZN

AstraZeneca

$32.39

-0.53 (-1.61%)

PFE

Pfizer

$33.28

0.06 (0.18%)

NVS

Novartis

$82.55

-0.66 (-0.79%)

  • 16

    Jul

  • 18

    Jul

  • 01

    Aug

  • 02

    Aug

  • 03

    Aug

  • 27

    Aug

AZN AstraZeneca
$32.39

-0.53 (-1.61%)

06/27/17
06/27/17
NO CHANGE

Large cap pharma could benefit from upcoming executive order, says Wells Fargo
Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm says the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/05/17
SBSH
07/05/17
DOWNGRADE
SBSH
Neutral
GlaxoSmithKline downgraded to Neutral from Buy at Citi
Citi analyst Andrew Baum downgraded GlaxoSmithKline (GSK) to Neutral and lowered his price target for the shares to GBP 17 from GBP 18. The analyst believes the market is underappreciating the slowing of the company's HIV market growth. He prefers shares of AstraZeneca (AZN), Roche (RHHBY) and Bayer (BAYRY) for exposure to Europe.
07/13/17
LEER
07/13/17
NO CHANGE
LEER
Outperform
AstraZeneca CEO departure now would have 'terrible' optics, says Leerink
Leerink analyst Seamus Fernandez said the media report that AstraZeneca (AZN) CEO Pascal Soriot may be leaving the company to take over at Teva (TEVA) comes as a "major surprise," adding that while the company would not comment to him on the rumor it also did not outright deny the report. While the news does not appear to be related to the outcome of the MYSTIC trial in non-small cell lung cancer, the optics around such a departure at this would be "terrible" and his loss would be a "clear negative" for AstraZeneca, according to Fernandez, who has an Outperform rating on Astra shares.
07/13/17
SBSH
07/13/17
NO CHANGE
Target $42
SBSH
Buy
Teva landing Soriot would be 'material positive,' says Citi
Citi analyst Liav Abraham believes Calcalist's report of Teva (TEVA) hiring away AstraZeneca's (AZN) CEO Pascal Soriot has credibility given the "relatively accurate track record" of the Israeli press in the "leaking" of information pertaining to Teva. The news, if confirmed, would be a "material positive" for Teva over the near to medium term, Abraham tells investors in a research note. She believes Soriot would "lend significant credibility" to Teva's turnaround thesis. On the other side, Soriot leaving would increase concerns over the pending outcome of AstraZeneca's MYSTIC trial, which constitutes the dominant near-term driver for the shares, Abraham argues. She has a Buy rating on Teva with a $42 price target. The stock in premarket trading is up 2% to $32.80. AstraZeneca is down 14c to $32.78.
PFE Pfizer
$33.28

0.06 (0.18%)

06/07/17
FBCO
06/07/17
NO CHANGE
Target $38
FBCO
Outperform
ASCO meeting highlights pressure on Pfizer cancer assets, says Credit Suisse
Credit Suisse analyst Vamil Divan said he came away from the ASCO meeting feeling like positive progress by competitors is increasing the pressure on Pfizer's (PFE) cancer assets, specifically pointing to positive data for Roche's (RHHBY) Alecensa, Johnson & Johnson's (JNJ) Zytiga and Eli Lilly's (LLY) abemaciclib. Additionally, competition in the immune-oncology and PARP spaces will make it more challenging for Pfizer to gain traction, added Divan. He keeps an Outperform rating on Pfizer, citing valuation and its dividend yield, but he has concerns about its upcoming patent expirations and growth products.
06/29/17
JEFF
06/29/17
UPGRADE
Target $117
JEFF
Buy
Icon upgraded to Buy from Hold at Jefferies
Jefferies analyst David Windley upgraded Icon (ICLR) to Buy saying the shares continue to trade at a group discount. The analyst sees "solid appreciation potential" as Pfizer (PFE) concentration is reduced and potentially 45% upside with a more aggressive acquisition strategy. The company's management has talked more openly about larger deals, Windley tells investors in a research note. Windley raised his price target for Icon shares to $117 from $86.
06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
NVS Novartis
$82.55

-0.66 (-0.79%)

07/10/17
JEFF
07/10/17
NO CHANGE
Target $121
JEFF
Buy
Jefferies ups Kite target to $121 on 'relatively benign' FDA docs
Jefferies analyst Biren Amin raised his price target for Kite Pharma (KITE) shares to $121 from $101 after the FDA posted briefing documents ahead of the July 12 committee meeting disusing Novartis' (NVS) CAR-T therapy CTL019. The documents for the first CAR-T therapy seem "relatively benign," Amin tells investors in a research note. The FDA's view of CAR-T therapies looks in-line with expectations, but the agency may require long-term follow-up of patients to assess for risk of secondary malignancies, Amin writes. He keeps a Buy rating on Kite Pharma. The stock in late morning trading is down 3% to $102.55.
07/12/17
RHCO
07/12/17
NO CHANGE
Target $108
RHCO
Buy
bluebird bio recent weakness unwarranted, says SunTrust
SunTrust analyst Edward Nash views the weakness in bluebird bio (BLUE) shares since the FDA briefing document on Novartis' (NVSR) CAR T product candidate as unwarranted. The tone of the briefing document is neutral and emphasizes short-term toxicities observed in Novartis' studies and long-term safety concerns so that the Advisory Committee will be able to conduct a thorough discussion to determine the risk/benefit ratio, Nash tells investors in a research note. Further, he believes the data from Novartis and bluebird are not an apples-to-apples comparison and reminds investors of the "differentiated safety profile" that bluebird's bb2121 has demonstrated to date. He recommends buying bluebird on the recent selloff and reiterates a Buy rating on the name with a $108 price target.
07/13/17
SBSH
07/13/17
NO CHANGE
SBSH
Novartis vote bodes well for Kite and Juno, says at Citi
Citi analyst Robyn Karnauskas believes the FDA's unanimous vote in favor of Novartis' (NVS) CAR-T bodes well for Kite Pharma (KITE) and Juno Therapeutics (JUNO). Yesterday's panel meeting provides a preview of what Kite can expect ahead of its November 29 FDA action date, Karnauskas tells investors in a research note. She believes the expert commentary from the panel has "overarching implications" for Kite and Juno, both of which are developing CAR-T therapies for multiple indications.
07/05/17
FBCO
07/05/17
DOWNGRADE
FBCO
Underperform
Novartis downgraded to Underperform from Neutral at Credit Suisse
Credit Suisse analyst Matthew Weston downgraded Novartis to Underperform with a price target of 77 francs.

TODAY'S FREE FLY STORIES

PFE

Pfizer

$33.60

-0.025 (-0.07%)

, MRK

Merck

$63.18

0.555 (0.89%)

10:26
07/20/17
07/20
10:26
07/20/17
10:26
Hot Stocks
Credit Suisse cuts Pfizer to hold, prefers Merck, J&J »

Credit Suisse downgraded…

PFE

Pfizer

$33.60

-0.025 (-0.07%)

MRK

Merck

$63.18

0.555 (0.89%)

JNJ

Johnson & Johnson

$136.04

0.83 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 01

    Aug

  • 02

    Aug

  • 03

    Aug

  • 09

    Aug

  • 27

    Aug

  • 22

    Sep

10:25
07/20/17
07/20
10:25
07/20/17
10:25
General news
U.S. leading economic index rose 0.6% to 127.8 in June »

U.S. leading economic…

C

Citi

$66.79

0.09 (0.13%)

10:25
07/20/17
07/20
10:25
07/20/17
10:25
Conference/Events
Citigroup to hold a conference call »

CFO Gerspach holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

  • 25

    Jul

STLD

Steel Dynamics

$37.49

0.99 (2.71%)

10:21
07/20/17
07/20
10:21
07/20/17
10:21
Hot Stocks
Breaking Hot Stocks news story on Steel Dynamics »

Steel Dynamics CEO says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

TSLA

Tesla

$325.26

-2.98 (-0.91%)

10:21
07/20/17
07/20
10:21
07/20/17
10:21
Hot Stocks
Citi awaits better Tesla entry point as bulls, bears both make good points »

Citi analyst Itay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 08

    Aug

  • 02

    Oct

VRTX

Vertex

$159.69

27.53 (20.83%)

10:20
07/20/17
07/20
10:20
07/20/17
10:20
Options
Large call spread in Vertex Pharm after yesterday's surge »

Large call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

10:20
07/20/17
07/20
10:20
07/20/17
10:20
General news
Treasury Action: longer yields rotated lower again »

Treasury Action: longer…

STLD

Steel Dynamics

$37.49

0.99 (2.71%)

10:19
07/20/17
07/20
10:19
07/20/17
10:19
Hot Stocks
Breaking Hot Stocks news story on Steel Dynamics »

Steel Dynamics cites…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

TSLA

Tesla

$325.26

-2.98 (-0.91%)

, JNJ

Johnson & Johnson

$136.03

0.82 (0.61%)

10:19
07/20/17
07/20
10:19
07/20/17
10:19
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

TSLA

Tesla

$325.26

-2.98 (-0.91%)

JNJ

Johnson & Johnson

$136.03

0.82 (0.61%)

TTS

Tile Shop

$14.83

-0.175 (-1.17%)

SBPH

Spring Bank Pharmaceuticals

$14.20

-0.12 (-0.84%)

DISCA

Discovery

$27.18

1.13 (4.34%)

SNI

Scripps Networks

$76.89

9.87 (14.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 08

    Aug

  • 09

    Aug

  • 09

    Aug

  • 02

    Oct

PFE

Pfizer

, RAD

Rite Aid

$2.50

-0.1322 (-5.03%)

10:19
07/20/17
07/20
10:19
07/20/17
10:19
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

PFE

Pfizer

RAD

Rite Aid

$2.50

-0.1322 (-5.03%)

FMSA

Fairmount Santrol

$3.63

-0.245 (-6.33%)

NEWR

New Relic

$47.96

-0.84 (-1.72%)

SND

Smart Sand

$7.87

0.25 (3.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 02

    Aug

  • 03

    Aug

  • 03

    Aug

  • 03

    Aug

  • 08

    Aug

  • 27

    Aug

  • 29

    Aug

NKE

Nike

$59.31

1.54 (2.67%)

, BGS

B&G Foods

$37.08

1.275 (3.56%)

10:18
07/20/17
07/20
10:18
07/20/17
10:18
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

NKE

Nike

$59.31

1.54 (2.67%)

BGS

B&G Foods

$37.08

1.275 (3.56%)

HPQ

HP Inc.

$18.86

0.155 (0.83%)

RCL

Royal Caribbean

$115.14

2.5775 (2.29%)

BWLD

Buffalo Wild Wings

$122.60

0.65 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 16

    Aug

  • 29

    Aug

  • 11

    Sep

STLD

Steel Dynamics

$37.49

0.99 (2.71%)

10:18
07/20/17
07/20
10:18
07/20/17
10:18
Hot Stocks
Steel Dynamics sees more stabilized scrap environment in 2H »

Comments from Q2 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

$NSD

NASDAQ Market Internals

10:17
07/20/17
07/20
10:17
07/20/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

10:16
07/20/17
07/20
10:16
07/20/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
07/20/17
07/20
10:15
07/20/17
10:15
General news
FX Action: The dollar »

FX Action: The dollar…

10:15
07/20/17
07/20
10:15
07/20/17
10:15
General news
Breaking General news story  »

Week of 7/14 EIA Natural…

RAD

Rite Aid

$2.50

-0.129 (-4.90%)

10:11
07/20/17
07/20
10:11
07/20/17
10:11
Hot Stocks
Rite Aid expands Naloxone dispensing program to Michigan, South Carolina »

Rite Aid announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHLB

Berkshire Hills Bancorp

10:10
07/20/17
07/20
10:10
07/20/17
10:10
Hot Stocks
Breaking Hot Stocks news story on Berkshire Hills Bancorp »

Berkshire Hills Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

AMZN

Amazon.com

$1,026.87

2.42 (0.24%)

, GOOG

Alphabet

$970.89

5.49 (0.57%)

10:10
07/20/17
07/20
10:10
07/20/17
10:10
Periodicals
AWS weighs new cloud service based on popular Google software, Information says »

Amazon Web Services…

AMZN

Amazon.com

$1,026.87

2.42 (0.24%)

GOOG

Alphabet

$970.89

5.49 (0.57%)

GOOGL

Alphabet Class A

$992.77

5.82 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

  • 24

    Jul

  • 27

    Jul

TMST

TimkenSteel

$16.00

-0.18 (-1.11%)

, STLD

Steel Dynamics

$37.49

0.99 (2.71%)

10:10
07/20/17
07/20
10:10
07/20/17
10:10
Recommendations
TimkenSteel, Steel Dynamics, AK Steel, U.S. Steel, Nucor analyst commentary  »

Cowen would be buying…

TMST

TimkenSteel

$16.00

-0.18 (-1.11%)

STLD

Steel Dynamics

$37.49

0.99 (2.71%)

AKS

AK Steel

$6.52

-0.08 (-1.21%)

X

U.S. Steel

$24.11

-0.36 (-1.47%)

NUE

Nucor

$59.14

-1.52 (-2.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

  • 20

    Jul

  • 25

    Jul

  • 26

    Jul

  • 01

    Aug

XBI

SPDR S&P BIOTECH

$79.80

0.69 (0.87%)

10:10
07/20/17
07/20
10:10
07/20/17
10:10
Options
Defensive option play in the SPDR Biotech ETF »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHLB

Berkshire Hills Bancorp

$36.60

0.1 (0.27%)

10:09
07/20/17
07/20
10:09
07/20/17
10:09
Earnings
Berkshire Hills Bancorp sees Q3 core EPS 58c, consensus 57c »

Sees total annualized…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

IRWD

Ironwood

$18.55

-0.23 (-1.22%)

10:07
07/20/17
07/20
10:07
07/20/17
10:07
Recommendations
Ironwood analyst commentary  »

Ironwood weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWLO

Twilio

$31.29

-0.21 (-0.67%)

10:07
07/20/17
07/20
10:07
07/20/17
10:07
Technical Analysis
Technical View: Twilio spikes higher on unconfirmed takeover rumors »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 08

    Aug

10:07
07/20/17
07/20
10:07
07/20/17
10:07
General news
Leading Indicators data reported »

June Leading Indicators…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.